Skip to content
10-K

Annual Report

Seres Therapeutics, Inc. MCRB

0000950170-25-038427

← back to feed
Filed
Mar 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 174.36M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $127.97M
Current Liabilities FY 2024 · Dec 31, 2023 $98.66M
Total Liabilities FY 2024 · Dec 31, 2023 $403.46M
Current Assets FY 2024 · Dec 31, 2023 $175.41M
Total Assets FY 2024 · Dec 31, 2023 $358.6M
Shares Diluted FY 2024 · Dec 31, 2022 108.08M sh
Capex FY 2024 · Dec 31, 2022 $9.82M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$228.82M
Eps Diluted FY 2024 · Dec 31, 2022 −$2.31
Eps Basic FY 2024 · Dec 31, 2022 −$2.31
Sga Expense restated FY 2024 · Dec 31, 2022 $70.26M
Rd Expense restated FY 2024 · Dec 31, 2022 $109.65M
Net Income FY 2024 · Dec 31, 2022 −$250.16M
Operating Income restated FY 2024 · Dec 31, 2022 −$179.91M
Stockholders Equity FY 2024 · Dec 31, 2021 $131.51M